RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study

Edward E. Walsh, Robert Frenck, Ann R. Falsey, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman, Stephen Lockhart, Kathleen Neuzil, Mark J. Mulligan, Ruth Bailey, Kena A. Swanson, Ping Li, Kenneth Koury, Warren Kalina, David Cooper, Camila Fontes-Garfias, Pei-Yong Shi, Özlem Türeci, Kristin R. Tompkins, Kirsten E. Lyke, Vanessa Raabe, Philip R. Dormitzer, Kathrin U. Jansen, Uğur Şahin, William C. Gruber
doi: https://doi.org/10.1101/2020.08.17.20176651

Data Availability

Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual anonymized participant data.

https://www.pfizer.com/science/clinical-trials/trial-data-and-results

Back to top
Posted August 20, 2020.
Download PDF
Data/Code
Email
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Edward E. Walsh, Robert Frenck, Ann R. Falsey, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman, Stephen Lockhart, Kathleen Neuzil, Mark J. Mulligan, Ruth Bailey, Kena A. Swanson, Ping Li, Kenneth Koury, Warren Kalina, David Cooper, Camila Fontes-Garfias, Pei-Yong Shi, Özlem Türeci, Kristin R. Tompkins, Kirsten E. Lyke, Vanessa Raabe, Philip R. Dormitzer, Kathrin U. Jansen, Uğur Şahin, William C. Gruber
medRxiv 2020.08.17.20176651; doi: https://doi.org/10.1101/2020.08.17.20176651
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area